A study co-led by UCLA scientists has found targeting a protein called endocan and its related signaling pathway could be a promising new approach for treating glioblastoma, an aggressive and lethal ...

A new University of Cincinnati Cancer Center study has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes.

A new University of Cincinnati Cancer Center study has identified a particular strand of microRNA as a promising new target ...

Nuvectis Pharma’s NXP800 shows potential in ovarian cancer but is early stage. Find out why NVCT stock is best suited for ...

The FDA previously designated the ADC as a breakthrough drug for relapsed or refractory extensive-stage small-cell lung cancer (SCLC), with the EMA awarding Priority Medicine (PRIME) status to the ...

Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

Researchers have developed a non-invasive method to improve the effectiveness of chemotherapy while reducing its harmful side effects. By applying brief, localized pulses of magnetic fields, the team ...

In a new study led by researchers at Karolinska Institutet in Sweden, AI models did a better job of detecting ovarian cancer than human doctors.

The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for avutometinib to be used in combination with defactinib for the treatment of adults with ...

Sutro Biopharma's valuation remains compelling despite recent market hits, with optimism for a turnaround. Click here to find ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...